How were Imunon's earnings last quarter?

Imunon, Inc. (NASDAQ:CLSN) released its quarterly earnings data on Monday, August, 15th. The biotechnology company reported ($0.87) earnings per share for the quarter, beating analysts' consensus estimates of ($1.12) by $0.25. Imunon had a negative net margin of 5,229.80% and a negative trailing twelve-month return on equity of 50.18%. During the same period last year, the business posted ($0.90) earnings per share.

When did Imunon's stock split?

Imunon shares reverse split before market open on Tuesday, March 1st 2022. The 1-15 reverse split was announced on Tuesday, March 1st 2022. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, March 1st 2022. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split.

What other stocks do shareholders of Imunon own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Imunon investors own include Zosano Pharma (ZSAN) , Sorrento Therapeutics (SRNE) , Matinas BioPharma (MTNB) , Novan (NOVN) , Dynavax Technologies (DVAX) , SCYNEXIS (SCYX) , ADMA Biologics (ADMA) , Aeterna Zentaris (AEZS) , Agenus (AGEN) and CBL & Associates Properties (CBL) .

NASDAQ:CLSN

Imunon (CLSN) Stock Price, News & Analysis

→ The “Perfect Storm” for Gold (From Gold Safe Exchange) (Ad)

Free CLSN Stock Alerts

Notice: This company has been marked as potentially delisted and may not be actively trading.

Compare

Today's Range: N/A
50-Day Range: $1.95
▼
$2.63
52-Week Range: N/A

Volume: 711 shs
Average Volume: 150,471 shs
Market Capitalization: $13.91 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: N/A

Stock Analysis

Get Imunon alerts:

Ad Gold Safe Exchange

The “Perfect Storm” for Gold

Gold has already reached all-time highs, and experts believe it's not slowing down any time soon. In fact, some analysts predict a $7,000 price tag by 2025.

Click here now to download the free Precious Metals Buying Guide!

About Imunon Stock (NASDAQ:CLSN)

Celsion Corporation, a clinical stage biotechnology company, focuses on the development and commercialization of DNA-based immunotherapies, vaccines, and directed chemotherapies. Its product pipeline includes GEN-1, a DNA-based immunotherapy for the localized treatment of ovarian cancer; and ThermoDox, a proprietary heat-activated liposomal encapsulation of doxorubicin, which is in development stage for various cancer indications. The company also has two feasibility stage platform technologies for the development of nucleic acid-based immunotherapies, vaccines, and other anti-cancer DNA or RNA therapies. Celsion Corporation was founded in 1982 and is based in Lawrenceville, New Jersey.

Ad Gold Safe Exchange

The “Perfect Storm” for Gold

Gold has already reached all-time highs, and experts believe it's not slowing down any time soon. In fact, some analysts predict a $7,000 price tag by 2025.

Click here now to download the free Precious Metals Buying Guide!

CLSN Stock News Headlines

March 10, 2024 | morningstar.com

Imunon Inc IMNN

May 22, 2023 | lse.co.uk

CLSN.L Regulatory News

April 19, 2024 | Gold Safe Exchange (Ad)

The “Perfect Storm” for Gold

Gold has already reached all-time highs, and experts believe it's not slowing down any time soon. In fact, some analysts predict a $7,000 price tag by 2025.

October 9, 2022 | marketscreener.com

Celsion Corporation Advances Proof of Concept to Non-human Primate Challenge Study Against SARS-CoV-2 with In-Process Vaccine Candidate - Marketscreener.com

October 3, 2022 | globenewswire.com

Imunon Reports Partial Results from Ongoing Non-human Primate Study - GlobeNewswire

October 3, 2022 | globenewswire.com

Imunon Appoints James E. Dentzer to its Board of Directors - GlobeNewswire

September 29, 2022 | globenewswire.com

Imunon Reports Inducement Grants under NASDQ Listing Rule 5646(c)(4) - GlobeNewswire

September 28, 2022 | globenewswire.com

IMUNON to Present at Chardan's 6th Annual Genetic Medicines - GlobeNewswire

April 19, 2024 | Gold Safe Exchange (Ad)

The “Perfect Storm” for Gold

Gold has already reached all-time highs, and experts believe it's not slowing down any time soon. In fact, some analysts predict a $7,000 price tag by 2025.

September 19, 2022 | globenewswire.com

Celsion Corporation Announces Company Name Change to Imunon, Inc. - GlobeNewswire

September 19, 2022 | finance.yahoo.com

Celsion Corporation Announces Company Name Change to Imunon, Inc.

September 15, 2022 | globenewswire.com

Celsion Completes Enrollment of the Phase I/II OVATION 2 Study with GEN-1 in Advanced Ovarian Cancer - GlobeNewswire

September 15, 2022 | finance.yahoo.com

Celsion Completes Enrollment of the Phase I/II OVATION 2 Study with GEN-1 in Advanced Ovarian Cancer

September 12, 2022 | benzinga.com

Celsion (NASDAQ:CLSN) – Celsion Corporation Presentation Time at the H.C. Wainwright 24th Annual Global I - Benzinga

September 12, 2022 | finance.yahoo.com

Celsion Corporation Presentation Time at the H.C. Wainwright 24th Annual Global Investment Conference Changed to 4:30 p.m. ET on September 13

September 9, 2022 | benzinga.com

Celsion (NASDAQ:CLSN) – Celsion Earnings Perspective: Return On Capital Employed - Benzinga

September 9, 2022 | msn.com

Celsion Earnings Perspective: Return On Capital Employed

September 7, 2022 | benzinga.com

Celsionoration (CLSN) – Celsion Corporation to Present at the H.C. Wainwright 24th Annual Global Investme - Benzinga

September 7, 2022 | globenewswire.com

Celsion Corporation to Present at the H.C. Wainwright 24th - GlobeNewswire

September 7, 2022 | finance.yahoo.com

Celsion Corporation to Present at the H.C. Wainwright 24th Annual Global Investment Conference

September 5, 2022 | reuters.com

CLSN.OQ - Celsion Corporation | Stock Price & Latest News | Reuters

September 1, 2022 | globenewswire.com

Celsion Corporation Highlights Progress in its DNA-based Vaccine Program - GlobeNewswire

September 1, 2022 | finance.yahoo.com

Celsion Corporation Highlights Progress in its DNA-based Vaccine Program

August 30, 2022 | finance.yahoo.com

CLSN: Complete Enrollment of OVATION 2 Study Expected in 3Q22…

August 15, 2022 | seekingalpha.com

Celsion GAAP EPS of -$0.87, revenue of $0.13M - Seeking Alpha

August 15, 2022 | marketscreener.com

CELSION CORP MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS. (form 10-Q) - Marketscreener.com

August 15, 2022 | benzinga.com

Recap: Celsion Q2 Earnings - Benzinga

See More Headlines

Receive CLSN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Imunon and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 8/15/2022
Today: 4/19/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Pharmaceutical Preparations
Sub-Industry: N/A
Current Symbol: NASDAQ:CLSN
CUSIP: N/A
CIK: 749647
Web: www.celsion.com
Phone: (609) 896-9100
Fax: 609-896-2200
Employees: 27
Year Founded: 1982

Profitability

EPS (Most Recent Fiscal Year): N/A
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-20,770,000.00
Net Margins: -5,229.80%
Pretax Margin: -5,506.60%
Return on Equity: -50.18%
Return on Assets: -36.94%

Debt

Debt-to-Equity Ratio: 0.13
Current Ratio: 6.52
Quick Ratio: 6.52

Sales & Book Value

Annual Sales: $500,000.00
Price / Sales: 0.00
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $9.66 per share
Price / Book: N/A

Miscellaneous

Outstanding Shares: 7,099,000
Free Float: 6,768,000
Market Cap: $13.91 million
Optionable: Optionable
Beta: 2.27

Social Links

7 Stocks to Own Before the 2024 Election

Looking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.

Get This Free Report

Key Executives

Mr. Michael H. Tardugno (Age 71)
Exec. Chairman
Comp: $1.01M
Mr. Jeffrey W. Church CPA (Age 65)
CPA, CFO, Exec. VP & Corp. Sec.
Comp: $528.54k
Dr. Khursheed Anwer M.B.A. (Age 62)
Ph.D., Exec. VP & Chief Scientific Officer
Comp: $511.92k
Dr. Nicholas Borys (Age 63)
Exec. VP & Chief Medical Officer
Comp: $586.54k
Dr. Corinne Le Goff M.B.A.
Pharm.D., CEO, Pres & Director
Mr. Timothy J. Tumminello (Age 64)
Chief Accounting Officer & Controller
Ms. Marianne M. Lambertson
VP of Communications & Investor Relations

Key Competitors

View All Competitors

CLSN Stock Analysis - Frequently Asked Questions

How were Imunon's earnings last quarter?: Imunon, Inc. (NASDAQ:CLSN) released its quarterly earnings data on Monday, August, 15th. The biotechnology company reported ($0.87) earnings per share for the quarter, beating analysts' consensus estimates of ($1.12) by $0.25. Imunon had a negative net margin of 5,229.80% and a negative trailing twelve-month return on equity of 50.18%. During the same period last year, the business posted ($0.90) earnings per share.
When did Imunon's stock split?: Imunon shares reverse split before market open on Tuesday, March 1st 2022. The 1-15 reverse split was announced on Tuesday, March 1st 2022. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, March 1st 2022. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split.
What other stocks do shareholders of Imunon own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Imunon investors own include Zosano Pharma (ZSAN), Sorrento Therapeutics (SRNE), Matinas BioPharma (MTNB), Novan (NOVN), Dynavax Technologies (DVAX), SCYNEXIS (SCYX), ADMA Biologics (ADMA), Aeterna Zentaris (AEZS), Agenus (AGEN) and CBL & Associates Properties (CBL).

This page (NASDAQ:CLSN) was last updated on 4/19/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Imunon (CLSN) Stock Price, News & Analysis

About Imunon Stock (NASDAQ:CLSN)

CLSN Stock News Headlines

Company Calendar

Industry, Sector and Symbol

Profitability

Debt

Sales & Book Value

Miscellaneous

Social Links

Key Executives

Key Competitors

CLSN Stock Analysis - Frequently Asked Questions

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info